Clinical applications of MAO-inhibitors

Current Medicinal Chemistry

Volumn 11, Issue 15, 2004, Pages 2033-2043

  Riederer, Peter ^a   Lachenmayer, L ^b   Laux, G ^c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Allgemeines Krankenhaus Eilbek   (Germany)

^c District Hospital Gabersee   (Germany)

Author keywords

Lacabemide; Moclobemide; Monoamine oxidase inhibitors; Neuroprotection; Rasagiline; Selegiline

Indexed keywords

ALPHA TOCOPHEROL; AMITRIPTYLINE; AMPHETAMINE; BROMOCRIPTINE; CITALOPRAM; CLOMIPRAMINE; DOXEPIN; FLUOXETINE; IMIPRAMINE; IPRONIAZID; ISOCARBOXAZID; LAZABEMIDE; LEVODOPA; MAPROTILINE; METHAMPHETAMINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NIALAMIDE; NORTRIPTYLINE; PARGYLINE; PHENELZINE; RASAGILINE; SAFRAZINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOLOXATONE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; XYLOPAR;

AGITATION; ALZHEIMER DISEASE; BEHAVIOR DISORDER; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; DEPRESSION; DIZZINESS; DRUG FATALITY; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESEARCH; DRUG SYNTHESIS; DRUG WITHDRAWAL; DYSKINESIA; EVIDENCE BASED MEDICINE; FOOD DRUG INTERACTION; GASTROINTESTINAL DISEASE; HALLUCINATION; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; INSOMNIA; LIVER TOXICITY; MENTAL DISEASE; NAUSEA; NERVOUSNESS; NEUROLOGIC DISEASE; NEUROPROTECTION; ORTHOSTATIC HYPERTENSION; ORTHOSTATIC HYPOTENSION; PANIC; PARKINSON DISEASE; PSYCHOMOTOR DISORDER; PSYCHOSIS; RESTLESSNESS; REVIEW; RISK BENEFIT ANALYSIS; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOCIAL PHOBIA; TREMOR; VERTIGO; WEIGHT GAIN; XEROSTOMIA;

EID: 3242772321     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/0929867043364775     Document Type: Review

References (111)

1. Bernheimer, H.; Birkmayer, W.; Hornykiewicz, O.; Wien. Klin. Wschr., 1962, 74, 558, 559
2. Berlin, I.; Said, S.; Spreux-Varoquaux, O.; Clin. Pharmacol. Ther., 1995, 58, 444, 452.
3. Trott, G.; Friese, H.; Menzel, M.; Nissen, G.; Psychopharmacology, 1992, 106 (suppl.), 134, 136.
4. Chan-Palay, V.; Psychopharmacology, 1992, 106 (suppl.) 137, 139.
5. Mahmood, I. Clin. Pharmacokinetics, 1997, 33, 91.
6. Haberle, D.; Szoko, E.; Magyar, K. Curr. Med. Chem., 2002, 9, 47.
7. Clarke, A.; Brewer, F; Johnson, E.S.; Mallard, N.; Hartig, F; Taylor, S; Corn, T.H. J. Neural. Transm., 2003 (in press).
8. Clarke, A.; Johnson, E.S.; Mallard, N.; Corn, T.H.; Johnston, A.; Boyce, M.; Warrington, S. J. Neural. Transm., 2003 (in press).
9. The Parkinson Study Group New Engl. J. Med., 1993, 328, 176.,
10. The Parkinson Study Group Ann. Neurol., 1993, 33, 350.
11. The Parkinson Study Group Arch. Neurol. 1994, 51, 342.
12. The Parkinson Study Group Ann. Neurol., 1996, 39, 29.,
13. The Parkinson Study Group Ann. Neurol., 1996, 39, 37.,
14. The Parkinson Study Group Ann. Neurol. 1996, 40, 99.
15. Finberg, J.P.; Tenne, M.; Youdim, M.B. Br. J. Pharmacol., 1981, 73, 65.
16. Rabey, J.M.; Sagi, I; Huberman, M.; Melamed, E.; Korczyn, A.; Giladi, N.; Inzelberg, R.; Djaldetti, R.; Klein, C.; Berecz, G. Clin. Neuropharmacol., 2000. 23, 324.
17. The Parkinson Study Group Arch. Neurol., 2002, 59, 1937.
18. Knoll, J.; Magyar, K. Adv. Biochem. Psychopharmacol., 1972, 5, 393.
19. Birkmayer, W.; Riederer, P; Youdim, M.B.H.; Linauer, W. J. Neural. Transm., 1975, 36, 303.
20. The Parkinson Study Group N. Engl. J. Med., 1989, 321, 1364.
21. Myllylä, V.V.; Sotaniemi, K.A.; Vuorinen, J.A.; Heinonen, E.A. Neurology, 1992, 42, 339.
22. Allain, H.; Pollak, P.; Neukirch, H.C. Mov. Disord., 1993, 8 (Suppl. 1), 36.
23. Mally, J.; Kovacs, A.B.; Slone, T.W. J. Neurol. Sci., 1995, 134, 143.
24. Palhagen, S.; Heinonen, E.H.; Hagglund, J.; Kaugedaar, T.; Kontants, H.; Maki-Ikola, O.; Palm, R.; Turunen, J. Neurology, 1998, 51, 520
25. Presthus, J.; Hajba, A. Acta Neurol. Scand., 1983, 68 (suppl. 95), 127.
26. Fischer, P.A.; Baas, H. J. Neural. Transm., 1987, (suppl. 25), 123.
27. Rinne, U.K J. Neural Transm., 1987, 25, 149.
28. Yahr, M.D. Acta Neurol. Scand., 1989, 126, 157.
29. Przuntek, H.; Kuhn, W. J. Neural. Transm., 1987, 25, 97.
30. Sivertsen, B.; Dupont, E.; Mikkelsen, B.; Mogensen, P.; Rasmussen, C.; Boe, F.; Heinonen, E. Acta Neurol. Scand, 1989, 126, 147.
31. Lees, A.J. (on behalf of the Parkinson's disease research group of the United Kingdom), BMJ 1995, 311, 1602.
32. Larsen, J.P.; Boas, J. Movement Disorders, 1997, 12, 173.
33. Przuntek, H.; Conrad, B.; Dichgans, J.; Kraus, P.H.; Krauseneck, P.; Pergande, G.; Rinne, U.; Schimrigk, K.; Scgnitker, J.; Vogel, H. P. Eur. J. Neurol., 1999, 6, 141.
34. Lees, A.J.; Shaw, K.M.; Kohout, L.J.; Stern, G.M.; Elsworth, J.D.; Sandler, M.; Youdim, M.B. Lancet, 1977, 2, 791.
35. Lieberman, A.N.; Gopinathan, G.; Neophytides, A.; Foo, S.H. N. Y. State J. Med., 1987, 87, 646.
36. Golbe, L.I.; Lieberman, A.N.; Muenter, M.D.; Ahlskog, J.E.; Gopinathan, G.; Neophytides, A.N.; Foo, S.H.; Duvoisin, R.C. Clin. Neuropharmacol., 1988, 11, 45.
37. Birkmayer, W.; Knoll, J.; Riederer, P.; Youdim, M.B.H.; Hars, V; Marton, J. J. Neural. Transm., 1985, 64, 113.
38. Gerlach, M.; Riederer, P.; Youdim, M.B.H. Europ. J. Pharmacol., 1992, 226, 97.
39. Olanow, C.W.; Riederer, P. Neurology, 1996, 47 (Suppl. 3), 51.
40. Langston, J.W.; Ballard, P.A.; Tetrud, J.W.; Irwin, I. Science, 1983, 219, 979.
41. Cohen, G.; Pasik, P.; Cohen, B.; Leist, A.; Mytilineou, C.; Yahr, M.D. Eur. J. Pharmacol., 1984, 106, 209.
42. Tetrud, J.W.; Langston, J.W. Science, 1989, 245, 519.
43. Schulzer, M.; Mark, E.; Calne, D.B. Ann. Neurol., 1992, 32, 795.
44. Ward, C.D. J. Neurol. Neurosurg. Psychiatry, 1994, 57, 217.
45. Shoulson, I.; Oakes, D.; Fahn, S.; Lang, A.; Langston, W.; LeWitt, P., Olanow, C.W.; Penney, J.B.; Tanner, C.; Kieburtz, K.; Rudolph, A. Ann. Neurol., 2002, 51, 604.
46. Olanow, C.W.; Hauser, R.A.; Gauger, L.; Malapira, T.; Koller, W.; Hubble, J.; Bushenbark, K.; Lilienfeld, D.; Esterlitz, J. Ann. Neurol., 1995, 38, 771.
47. Stocchi, F.; Olanow, C.W. Ann. Neurol. 2003, 53 (Suppl. 3), S87.
48. Fowler, J.S.; Volkow, N.D.; Logan, J.; Wang, G.J.; MacGregor, R.R.; Schlyer, D.; Wolf, A.P.; Pappas, N.; Alexoff, D.; Shea, C.; Dorflinger, E.; Kruchowy, L.; Yoo, K.; Fazzini, E.; Patlak, C. Synapse, 1994, 18, 86.
49. Gerlach, M.; Riederer, P. In Neuropathologie des Parkinson-Syndroms und neue Entwicklungen in der Therapie, Oertel, W.H., Ed.; Editiones Roche, Basel, 2003, 79.
50. Youdim, M.B.H.; Tipton, K,F. Parkinsonism Relat. Disord., 2002, 8, 247.
51. Green, A. R.; Mitchell, B. D.; Tordoff A., F., C.; Youdim, M., B., H.; Br. J. Pharmacol., 1977, 60, 343, 349.
52. Goetz, C.G.; Koller, W.C.; Poewe, W., Rascol, O.; Sampaio, C. Movement Disorders, 2002, 17 (Suppl. 4), S38.
53. Wilcock, G.K.; Birks, J.; Whitehead, A.; Evans, J.G. Internat. J. Geriatric Psychiatry, 2002, 17, 175.
54. Riederer P., Danielczyk W, Grünblatt E. Neuro. Toxicology, 2003, (In press).
55. Rascol, O.; Payoux, P.; Ory, F.; Ferreira, J.J.; Brefel-Courbon, C.; Montastruc, J.L. Ann. Neurol., 2003, 53 (Suppl. 3), S3.
56. Bhattacharya, K.F.; Nouri, S; Olanow, C.W., Yahr, M.D., Kaufmann, H. Parkinsonism Relat. Disord., 2003, 9, 221.
57. Ben-Shlomo, Y; Churchyard, A.; Head, J.; Hurwitz, B.; Overstall, P.; Ockelford, J; Lees, A.J. Br. Med. J. 1998, 18, 1191.
58. Foley, P.; Gerlach, M.; Youdim, M.B.H.; Riederer, P. Parkinsonism Relat. Disord, 2000, 6, 25.
59. Donnan, P.T.; Steinke, D.T.; Stubbings, C.; Davey, P.G.; MacDonald, T.M. Neurology, 2000, 55, 1785.
60. Olanow, C.W.; Myllylä, V.V.; Sotaniemi, K.A.; Larsen, J.P.; Palhagen, S.; Przuntek, H.; Heinonen, E.H.; Kilkku, O.; Lammintausta, R; Mäki-Ikola, O.; Rinne, U.K. Neurology, 1998, 51, 825.
61. Pare, C.; Br. J. Psychiatry, 1985, 146, 576.
62. Paykel, E.; White, J.; Br. J. Psychiatry, 1989, 155 (suppl. 6), 9.
63. Nolen, W.; Hoencamp, I.; Haffmans, P.M.J. in John Wiley & Sons Ltd., 1994, Nolen, W.A.; Zohar, J.; Roosem S.P.; Amsterdam, J.D. (eds.), pp. 129.
64. Laux G, Psychiatr Prax., 1989, 16 (Suppl. 1), 37.
65. Fitton, A.; Faulds, D.; Goa, K. Drugs, 1992, 43, 561.
66. Fulton, B.; Benfield, P. Drugs, 1996, 52, 450.
67. Laux, G.; Becker, T.; Müller, U. Springer, 2002, 489.
68. Güntert, T.W.; Banken, L.; Hilton, S.; Holfort, N.H. J. Clin. Psychopharmacol., 1995, 15, (suppl. 2). 84.
69. Angst, J.; Amrein, R.; Stabl, M. J. Clin. Psychopharmacol., 1995, 15 (Suppl. 2), 16.
70. Gattaz, W.; Vogel, P.; Kick, H.; J. Clin. Psychopharmacol., 1995, 15 (suppl. 2), 35.
71. Lonnqvist, J.; Sihvo, S.; Syvälahti, E. J. Affect Disord., 1994, 32, 169.
72. Bakish, D.; Hooper, C.; West, D. Hum. Phsychopharmacol., 1995, 10, 109.
73. Riederer, P.; Laux, G.; Pöldinger, W. Neuro-Psycho-Pharmaka, 1993, 269.
74. Liebowitz, M.; Schneier, F.; Campeas, R.; Hollander, E.; Hatterer, J.; Fyer, A.; Gorman, J.; Papp, L.; Davies, S.; Gully R.; et al. Arch. Gen. Psychiatry, 1992, 49, 290.
75. Heimberg, R.; Liebowitz, M.; Hope, D.A.; Schneier, F.R.; Holt, C.S.; Welkowitz, L.A.; Juster, H.R.; Campeas, R.; Bruch, M.A.; Cloitre, M.; Fallon, B.; Klein, D.F. Arch. Gen. Psychiatry, 1998, 55, 1133.
76. Ballenger, J.; Wheadon, D.; Steiner, M. Bushnell, W.; Gergel, I.P. Am. J. Psychiatry, 1998, 155, 36.
77. van Ameringen, M.; Mancini, C.; Oakman, J.M.; Farvolden P. CNS-Drugs, 1999, 11: 307.
78. Lydiard, R.; Ballenger, J. J. Affect Disord., 1987, 13, 153.
79. Tryrer, P.; Shawcross, C. J. Psychiat. Res., 1988, 22 (suppl 1), 87.
80. Quitkin, F.; McGrath, P.; Stewart, J. Arch. Gen. Psychiatry, 1990, 47, 935.
81. Amsterdam, J.; Berwish, N.; Pharmacopsychiatry, 1989, 22, 21.
82. Guze, B.; Baxter, L.; Rego, J. J. Clin Psychiat., 1987, 48, 31.
83. Schmauss, M. Nervenarzt., 1996, 67, 390.
84. Atkinson, R.; Ditman, K.; Clin. Pharmacol. Ther., 1965, 6, 631.
85. Remick, R.; Froese, C.; Keller, F. Prog Neuropsychopharmacol. Biol. Psychiatry, 1989, 13, 497.
86. Moll, E.; Neumann, N.; Schmid-Burgk, W. Clin. Neuropharmacol., 1994, 17 (suppl. 1), 74.
87. Versiani, M.; Mardi, A.; Figueira, I. Acta Psychiatr. Scand., 1990, 360 (supple), 24.
88. Laux, G.; Philipp, M.; Kohnen, R. Lancet, 1996, 347, 1330.
89. Cantu, T.; Korek, J. Drug Intell. Clin. Pharm., 1988, 22, 755.
90. Hindmarch, I.; Alford, C.; Barwell, F. J. Psychopharmacol., 1992, 6, 198.
91. DeJonghe, F.; Swinkels, J. Drugs, 1992, 41 (suppl. 2) 40.
92. Chen, D.T.; Ruch, R. Clin. Neuropharmacol., 1993, 16 (Suppl), 63-68.
93. Neuvonen, P., Pohjola-sintonen, S.; Tacke, U. Lancet, 1993, 342, 1419.
94. Henry, J.; Alexander, C.; Sener, E. Br. Med. J., 1995, 310, 221.
95. Dingemanse, J. Int. Clin. Psychopharmacol., 1993, 7, 167.
96. Philipp, M.; Delini-Stula, A.; Baier, D.; Kohnen, R.; Scholz, H.; Laux, G. Int. J. Psychiatry Clin. Practice, 1999, 3, 257-264.
97. Sunderland, T.; Cohen, R.; Molchan, S. Arch. Gen. Psychiatry, 1994, 51, 607.
98. Laux, G.; Scholz, H.; Baier, D. Psychopharmakotherapie, 1994, 1 (suppl 2), 19.
99. Bodkin, J. APA, 2001, 154.
100. Carl, G.; Laux, G.; Psychiatr. Prax., 1990, 17, 26.
101. Isacsson, G.: Holmgren, P.; Druid, H.; Bergman, U. Acta Psychiat. Scand, 1992, 6, 198.
102. Nair, N.P.; Ahmed, S.K.; Kn, N.M.; West, T.E. Acta Psychiatr. Scand., 1995, 386, (suppl.) 28.
103. Larsen, J.P.; Boas, J.; Erdal, J.E. Europ. J. Neurol. 1999, 6, 539.
104. Arnett, C.D.; Fowler, J.S.; MacGregor, P.R.; Schlyer, D.J.; Wolf, A.P.; Langström, B.; Halldin, J. Neurochem., 49, 1987, (suppl. 2), 522.
105. Versiani, M.; Nardi, A.E.; Mundim, F.D. Br. J. Psychiatry, 1992, 161, 353.
106. Katschnig, H.; Stein, M.B.; Buller, R. and the Int. Multicenter Clinical Trial Group on Moclobremide in Social Phobia, Eur. Arch. Psychiarry Clin. Neurosci., 1997, 247, 71.
107. Versiani, M.; Nardi, A.E.; Mundim, F.D.; Pinto, S.; Saboya, E.; Kovacs, R. Int. Clin. Psychopharmacol., 1996, (suppl. 3), 83-88.
108. Bjartveit, K.M.; Dahl, A, Eur arch Psychiatry Clin. Neurosci., 1999, (suppl. 1): 19.
109. Loerch, B.; Graf-Morgenstern, M.; Hautzinger, M.; Schlegel, S.; Hain, C.; Sandmann, J.; Benkert, O. Br. J. Psychiatry, 1999, 174, 205.
110. Tiller, J.; Bower, C.; Behnke, K. Eur. Arch. Psychiatry Clin. Neurosci., 1999, 249 (suppl. 1), 7.
111. Laux, G.; Volz, H.P.; Möller, H.J. CNS Drugs, 1995, 3, 145.